Peter Jahnmatz | BDD
Salipro Biotech AB

Festival of Biologics Day 3 @ 11:20

Overcoming GPCR Antibody Discovery Challenges: Next-Generation CXCR4 Antibodies

CXCR4 is a chemokine receptor upregulated in various cancers, yet developing therapeutic antibodies against it has proven challenging. The best-in-class antibody, Ulocuplumab, was discontinued in clinical development. To develop next generation CXCR4 antibodies, we isolated wildtype oligomeric CXCR4 antigen and generated a panel of novel CXCR4 antibodies which exhibit higher affinity and improved antagonistic properties compared to Ulocuplumab.Our work addresses a long-standing challenge in antibody drug development against GPCRs, including CXCR4, a key target in oncology. By leveraging the Salipro platform to extract native and functional membrane proteins and using phage display for antibody discovery, we demonstrate a breakthrough in generating high-affinity, antagonistic CXCR4 antibodies. Given the clinical setbacks of previous candidates like Ulocuplumab, these findings may have significant implications for antigen formulation and the creation of novel cancer therapeutics.

Peter Jahnmatz, BDD, Salipro Biotech AB

×

Peter Jahnmatz / Overcoming GPCR Antibody Discovery Challenges: Next-Generation CXCR4 Antibodies

Peter Jahnmatz, BDD,
Salipro Biotech AB

Peter Jahnmatz is BD Director at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Peter obtained his PhD in Immunology and Infectious disease from the Karolinska Institute, Sweden where he...

CloseMore